临床试验/PER-089-03

PER-089-03已完成未知

A STUDY OF PARALLEL DESIGN, MULTICENTER, DOUBLE BLIND, RANDOMIZED, CONTROLLED ON THE SAFETY AND EFFICACY OF TAK-559 COMPARED WITH PLACEBO IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2.

TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,0 个研究点目标入组 0 人开始时间: 2004年1月13日最近更新: 2023年9月4日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方: TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 0（—）

入选标准

•Patients who have been diagnosed with type 2 diabetes mellitus and who are being treated with insulin therapy. The patient should have a glycosylated hemoglobin Ale (HbAlc) <8.0%, fasting plasma glucose (GPA) <140 mg / dl, and a blood pressure control (PS) reading of <140/95 mmHg at the time of treatment. selection, be willing to sign the informed consent, and meet all the inclusion criteria specified in the protocol.

排除标准

•Patients will be excluded if they have a hypersensitivity to TAK-559 or its related components, obtain clinically significant results in physical examinations, electrocardiograms (ECG), echocardiograms, or clinical laboratory results, or if they are taking any medication excluded. In case the patient presents any of the exclusion criteria specified in the protocol, he will be excluded from the study.

研究者

发起方

TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER, INC.,

相似试验

Eficacia de TAK-559 en el tratamiento de sujetos con diabetes mellitus tipo 2.-E149 Unspecified diabetes mellitus, without complicationsUnspecified diabetes mellitus, without complicationsE149

PER-087-03TAKEDA PHARMACEUTICALS,

Improving immunisation timeliness in infants and young childreVaccine Preventable DiseasesImmunisation DeliveryImmunisation CoveragePublic Health - Other public health

ACTRN12616000204448Queensland University of Technology516

进行中（未招募）

RISK OF NOCTURNAL HYPOGLYCEMIA AND CRITICAL ARRHYTHMIAS WITH SITAGLIPTIN VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES

EUCTR2014-003792-34-DEGWT-TUD GmbH

A multicenter, randomized, parallel design, double-blind, superiority test, prospective clinical trial to confirm the safety and effectiveness of symptom improvement when applying low-output light irradiation device (Bye-Vi) to cold patients.

KCT0008894anobioimaging58

MULTICENTRIC DOUBLE BLIND RANDOMIZED PARALLEL STUDY CONTROLLED WITH PLACEBO AND ACTIVE COMPARATOR TO EVALUATE THE EFFECTIVENESS OF THE ALTERATION OF LIPIDS, SAFETY AND TOLERABILITY OF L-410198 IN PATIENTS WITH MIXED HYPERLIPIDEMIA (CHOLESTEROL AND ELEVATED TRIGLYCERIDES)

PER-030-00MERCK SHARP & DOHME PERU S.R.L.,